Hemorrhagic Cystitis Epidemiology

Hemorrhagic cystitis Trends

• Hemorrhagic cystitis is a relatively uncommon condition in the general population but remains a clinically significant complication among patients undergoing hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, or pelvic radiotherapy, where incidence rates are substantially higher than in the broader population.
• BK virus-associated hemorrhagic cystitis (BKV-HC) represents one of the most clinically significant forms of the disease in transplant recipients, with reported incidence rates ranging from approximately 10%–25% among allogeneic HSCT recipients, particularly in highly immunosuppressed patients.
• Male patients are generally reported to experience a slightly higher incidence of BK virus-associated hemorrhagic cystitis following HSCT.
• Pediatric and adolescent transplant recipients experience a disproportionately high burden of BK virus-associated hemorrhagic cystitis, with several studies reporting incidence rates exceeding 20% in certain high-risk transplant settings.
• The risk of hemorrhagic cystitis increases with the use of myeloablative conditioning regimens, unrelated donor transplants, cord blood transplantation, and prolonged immunosuppressive therapy, highlighting the importance of transplant-related risk factors in disease epidemiology.
• Hemorrhagic cystitis demonstrates a strong association with BK virus reactivation, with BK viruria and viremia serving as important predictors of disease development, severity, and clinical outcomes in transplant recipients.
• As the number of HSCT procedures continues to increase globally and survival outcomes improve, the prevalence of post-transplant complications such as hemorrhagic cystitis is expected to rise, expanding the addressable patient population during the forecast period.

Hemorrhagic cystitis Epidemiology Forecast in the United States

• 2025 Prevalent Cases of Hemorrhagic cystitis: ~XXXX
• Hemorrhagic cystitis Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Hemorrhagic cystitis Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Hemorrhagic cystitis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hemorrhagic cystitis Understanding and Diagnosis Algorithm

Hemorrhagic cystitis Overview and Diagnosis

Hemorrhagic Cystitis is an inflammatory bladder condition characterized by bladder mucosal injury and hematuria, ranging from microscopic bleeding to severe gross hematuria with clot formation. It most commonly occurs as a complication of chemotherapy, radiation therapy, or viral infections, particularly in immunocompromised patients undergoing hematopoietic stem cell transplantation (HSCT). Chemotherapy-induced cases are frequently linked to cyclophosphamide and ifosfamide, while BK virus reactivation is a leading cause of late-onset hemorrhagic cystitis in transplant recipients. Common symptoms include hematuria, dysuria, urinary frequency, urgency, suprapubic pain, and, in severe cases, urinary obstruction and renal impairment. As the use of HSCT and intensive cancer therapies continues to increase, the clinical burden of hemorrhagic cystitis is expected to rise, highlighting a significant unmet need for effective treatment options.

Diagnosis is primarily based on clinical presentation, patient history, and laboratory investigations to determine the underlying cause and severity of disease. Evaluation typically includes urinalysis, urine culture, blood tests, renal function assessment, and viral testing for BK virus or adenovirus in transplant recipients. Imaging studies may be used to assess clot retention or urinary tract obstruction, while cystoscopy can help evaluate bladder mucosal injury and exclude alternative causes of hematuria. Advances in molecular diagnostics, viral monitoring, and risk stratification are expected to improve disease detection and support more personalized management approaches.

Further details are provided in the report.

Hemorrhagic cystitis Epidemiology

Key Findings from Hemorrhagic cystitis Epidemiological Analysis and Forecast 

• According to the secondary research, BK polyomavirus-associated hemorrhagic cystitis (BKPyV-HC) occurs in approximately 7%–54% of adult and 8%–25% of pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), making it one of the most common infectious complications in the transplant setting.
• According to various studies, BK virus-associated hemorrhagic cystitis predominantly affects allogeneic HSCT recipients and is associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. The authors reported that the incidence of post-transplant BK virus-associated hemorrhagic cystitis varies considerably across studies, ranging from 7% to 54% in adult transplant recipients.
• According to Delveinsight estimates, hemorrhagic cystitis develops in approximately 9%–31% of stem cell transplant recipients, with severe cases associated with urinary tract obstruction, renal dysfunction, longer hospital stays, and increased treatment costs. BK virus reactivation represents one of the leading causes of late-onset disease.
• According to secondary research, approximately 80% of adults are seropositive for BK virus, and viral reactivation occurs primarily in immunocompromised individuals. Hemorrhagic cystitis represents the principal clinical manifestation of BK virus reactivation in HSCT recipients.
• According to secondary research, BK virus-associated hemorrhagic cystitis developed in approximately 13% of adult patients undergoing allogeneic HSCT in a large single-center analysis, with higher BK viremia levels correlating with greater disease severity.

Scope of the Report

The report covers a segment of an executive summary, a descriptive overview of Hemorrhagic Cystitis, explaining its causes, signs and symptoms, and pathogenesis. Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Hemorrhagic Cystitis Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Hemorrhagic Cystitis? What will be the growth opportunities across the 7MM concerning the patient population with Hemorrhagic Cystitis?
• What is the historical and forecasted Hemorrhagic Cystitis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.